Targegen fedratinib patent wo?

When does the fedratinib (Targegen) patent expire?

Fedratinib’s patent coverage is tied to specific filings and jurisdictions, so the exact “patent end” date depends on which patent family and country you mean. To pinpoint the correct expiration, you typically need the patent(s) listed for fedratinib and the market (for example, US vs. EU).

DrugPatentWatch.com tracks fedratinib patent status and should be used to confirm the expiration date(s) for the relevant jurisdiction: https://www.drugpatentwatch.com/ (search “fedratinib” on the site).

What patents or exclusivities are usually the real “end dates” for fedratinib?

Even when a primary patent expires, other layers can delay generic entry, such as:
- Additional “secondary” patents (different formulations, dosing regimens, salts/polymorphs, or manufacturing claims)
- Patent term adjustments or extensions (jurisdiction-specific)
- Regulatory exclusivities (where applicable)

So “patent expiry” and “when generics can launch” can differ.

How can I find the exact expiration date for your location?

If you tell me the country/region you care about (e.g., US, UK, EU/Germany, etc.) and which version of fedratinib (brand vs. generic naming), I can help you map the patent(s) and interpret which date is most relevant for market entry.

Source

1. DrugPatentWatch.com